Rucha Patil

Scientist at ICMR-NIIH My motto: Be fearless in the pursuit of what sets your soul on fire😊💃🏻

[ICMR NIRBID @IcmrNiih]

We are proud to share that Dr. Rucha Patil, Scientist D, has been conferred the Phoenix High Impact Innovation Award 2026 at Health AI Con 2026.

[IAHAD @IAHAD_updates]

Join the IAHAD Webinar (37th Series) 10 April, 6:30 PM IST
Topic: Practical Diagnosis of von Willebrand Disease
Dr. Jasmina Ahluwalia
Dr. Dinesh Chandra
Panel: Dr. Rajesh Phatale, Dr. Tulasi Geevar, Dr. Jasmita
https://t.co/73dCuECBzt
#Hematology #vWD #MedicalEducation #IAHAD

[ICMR NIRBID @IcmrNiih]

A timely article in Business Standard by Dr. Rucha Patil, ICMR-NIIH,Mumbai & Dr. Tulika, AIIMS, New Delhi, highlights why prophylactic treatment must move from an option to the standard of care for people with haemophilia. https://t.co/g6xWrSLWsS

[IAHAD @IAHAD_updates]

Join us for a special talk on “Haemophilia and Ageing” by Prof. Michael Makris
Moderated by Dr. Shashikant Apte
Followed by a clinical practice session
12 Dec 2025 6:30–8:00 PM IST
Register: https://t.co/73dCuECBzt
#Haemophilia #Ageing #Hematology

[Rucha Patil @RuchaPatil286]

First, global recognition at #ISTH2025
Now, celebrated at home too 🇮🇳
What a journey. What a team. 💪

https://t.co/8ZddTwcdK7

[Rucha Patil @RuchaPatil286]

@Brianhemophilia Thank you Sir

[Rucha Patil @RuchaPatil286]

@imkin @Brianhemophilia Treated and spontaneous bleeds are zero to 1. However you cant control traumatic bleeds.

[Brian O Mahony @Brianhemophilia]

Use of low dose (50%) Emicizumab in trial in India. Conclusions :0 ABR in >50% PWH.similar efficacy to full dose, cost effective, no safety issues.
Kmportant data

[Rucha Patil @RuchaPatil286]

@flora_peyvandi Yes there is a cut off after which there is no correlation. We will soon help define the cut off plasma emicizumab levels

[Rucha Patil @RuchaPatil286]

@flora_peyvandi Our randomised controlled trial data once published should be able to change the policy in low middle income countries. Thats the hope as its working so well #emicizumab #ISTH2025

[flora peyvandi @flora_peyvandi]

With all novel drugs in #Hemophilia it’s a time to focus on treatment of a larger number of patients who have no access for regular #prophylaxis #ISTH2025

[flora peyvandi @flora_peyvandi]

#Low dose #emicizumab in low resource countries

[flora peyvandi @flora_peyvandi]

Randomized trial with regular and low dose of emicizumab in Mumbai #ISTH2025

[flora peyvandi @flora_peyvandi]

No correlation between clinical manifestations and the #emicizumab concentration was seen in Mumbai trial with low and regular dose of emicizumab # ISTH2025

[flora peyvandi @flora_peyvandi]

Indian team from Mumbai report this conclusion to #ISTH2025

[ICMR NIRBID @IcmrNiih]

ICMR's NIIH develops simple point of care test for haemophilia A, Von Willebrand Disease: Media report.
https://t.co/2ySTzyqiOQ
@ICMRDELHI
@MoHFW_INDIA
@DeptHealthRes

[IAHAD @IAHAD_updates]

Call for Abstracts - NHU 2025
August 2–3, 2025 | Bengaluru, India
Abstract submissions are open. Don’t miss the chance to present your work!
https://t.co/RYfky4pLwt
#NHU2025 #callforabstracts #hemophilia

[IAHAD @IAHAD_updates]

National Haemostasis Update (NHU) 2025 is for healthcare professionals involved in the promotion of care of people with hemophilia and allied bleeding disorders in India. Join us.
August 2–3, 2025 | Bengaluru, India
To know more: https://t.co/KLRmv4vPpj
#bleeding #hemophilia

[IAHAD @IAHAD_updates]

Join for Nursing Webinar Series on “Building Resilience: Mental Health and Psycho-Social Support for Haemophilia Patients” by Ms. Cathy Harrison, Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom
Register: https://t.co/eIqCPVlsup

[Rucha Patil @RuchaPatil286]

WFH 2025 Summit, Dubai, U.A.E., April 23–25, 2025
@IAHAD_updates @HemoIndia and colleagues